FAS (P25445) variants and mutations
FAS (also known as P25445) is a human protein-coding gene encoding a tumor necrosis factor receptor superfamily member 6 protein. Its engagement by FAS ligand assembles a death-inducing signaling complex that triggers caspase-mediated apoptosis, particularly in activated lymphocytes. Loss-of-function variants can cause autoimmune lymphoproliferative syndrome by preventing normal contraction of immune responses. This analysis covers 643 FAS variants and mutations. Of these, 76% have computational variant effect predictions. Disease context includes autoimmune lymphoproliferative syndrome type 1, autoimmune lymphoproliferative syndrome, and lymphoid neoplasm. Example FAS variants include L2R, L2I, and L2P.
Variant analysis overview
- Gene: FAS
- Protein: P25445
- UniProt accession: P25445
- Organism: Homo sapiens
- Variants analyzed: 643
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 457 unspecified-consequence records; 109 missense variants; 65 synonymous variants; 4 stop-gained variants; 9 frameshift variants; 1 splice-region variants
- Prediction scores: 486 variants have prediction scores (76% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: autoimmune lymphoproliferative syndrome type 1, autoimmune lymphoproliferative syndrome, lymphoid neoplasm, lymphoma, neurodegenerative disease, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, hypothyroidism, hereditary disease, Hashimoto thyroiditis, adult T-cell leukemia/lymphoma, cutaneous melanoma.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 7 post-translational modification sites.
- Structural context: 172 variants have structural context.
- PTM context: 20 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable FAS variants
Examples include L2R, L2I, L2P, G3A, G3D, G3R, G3S, G3C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L2R (p.Leu2Arg), Ensembl rs903460339
- L2I (p.Leu2Ile), gnomAD 10-88989472-C-A, CADD 2.09
- L2P (p.Leu2Pro), gnomAD 10-88989473-T-C, CADD 4.84
- G3A (p.Gly3Ala), TOPMed rs1223868338, gnomAD rs1223868338, CADD 8.67, PolyPhen-2 0.01
- G3D (p.Gly3Asp), TOPMed rs1223868338, gnomAD rs1223868338
- G3R (p.Gly3Arg), ExAC rs759288204, gnomAD rs759288204, CADD 5.98, PolyPhen-2 0.64
- G3S (p.Gly3Ser), ExAC rs759288204, gnomAD rs759288204
- G3C (p.Gly3Cys), gnomAD 10-88989490-G-T, CADD 2.82
- G3G (p.Gly3Gly), gnomAD 10-88989492-C-T, CADD 4.62
- G3V (p.Gly3Val), rs1847040239, gnomAD 10-88989506-G-T, CADD 6.56
- I4M (p.Ile4Met), ExAC rs771825085, gnomAD rs771825085, CADD 14.90, PolyPhen-2 0.23, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- I4V (p.Ile4Val), gnomAD 10-88990886-A-G, CADD 2.53, PolyPhen-2 0.01
- I4N (p.Ile4Asn), gnomAD 10-88990887-T-A, CADD 12.40, PolyPhen-2 0.23
- W5* (p.Trp5Ter), TOPMed rs1290926270, gnomAD rs1290926270, CADD 37.00, Uncertain significance
- W5C (p.Trp5Cys), rs1290926270, ClinGen CA377505795, ClinVar RCV002628719, TOPMed rs1290926270, CADD 25.90, PolyPhen-2 0.89, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- T6S (p.Thr6Ser), Ensembl rs2133384363
- T6T (p.Thr6Thr), gnomAD 10-88990894-C-T, CADD 4.71
- L7F (p.Leu7Phe), ExAC rs775316075, gnomAD rs775316075
- L7H (p.Leu7His), Ensembl rs2133384423, Likely pathogenic
- L7P (p.Leu7Pro), rs2133384423, ClinGen CA377505811, NCI-TCGA Cosmic COSV5824, cosmic curated COSV58240, CADD 23.10, PolyPhen-2 0.46, Likely pathogenic, not provided; Autoimmune lymphoproliferative syndrome type 1
- L8L (p.Leu8Leu), rs760596246, gnomAD 10-88990900-A-G, CADD 6.85
- P9S (p.Pro9Ser), Ensembl rs1847138496
- P9P (p.Pro9Pro), rs199651217, gnomAD 10-88989513-T-C, CADD 4.97
- P9R (p.Pro9Arg), gnomAD 10-88989566-C-G, CADD 4.31
- P9L (p.Pro9Leu), gnomAD 10-88990902-C-T, CADD 8.40, PolyPhen-2 0.00
- P9H (p.Pro9His), gnomAD 10-88990902-C-A, CADD 14.70, PolyPhen-2 0.63
- L10P (p.Leu10Pro), TOPMed rs1353528671
- V11A (p.Val11Ala), rs761692893, ClinGen CA5593017, ClinVar RCV003870500, ExAC rs761692893, CADD 14.70, PolyPhen-2 0.06, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- V11L (p.Val11Leu), gnomAD 10-88989478-G-T, CADD 0.23
- V11E (p.Val11Glu), rs774692551, gnomAD 10-88989479-T-A, CADD 5.51
- V11V (p.Val11Val), rs1485747394, gnomAD 10-88989480-G-C, CADD 2.33
- L12F (p.Leu12Phe), ExAC rs772912891, gnomAD rs772912891, CADD 1.01, PolyPhen-2 0.01
- L12L (p.Leu12Leu), gnomAD 10-88989510-T-C, CADD 9.46
- T13A (p.Thr13Ala), gnomAD rs1848018768, CADD 0.39
- T13K (p.Thr13Lys), rs372880667, ClinGen CA377507258, ClinVar RCV003028505, ESP rs372880667, CADD 0.34, PolyPhen-2 0.41, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- T13M (p.Thr13Met), rs372880667, ClinGen CA5593020, cosmic curated COSV10609, ClinVar RCV001906205, CADD 4.06, PolyPhen-2 0.34, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1; Inborn genetic diseases
- T13S (p.Thr13Ser), rs1842954041, ClinGen CA916080417, ClinVar RCV001055690, NCI-TCGA TCGA novel, Pathogenic
- T13N (p.Thr13Asn), gnomAD 10-88989521-C-A, CADD 7.83
- T13T (p.Thr13Thr), rs754990444, gnomAD 10-88989522-T-C, CADD 5.29
- T13R (p.Thr13Arg), gnomAD 10-89003036-C-G, CADD 8.85, PolyPhen-2 0.61
- S14C (p.Ser14Cys), Ensembl rs1848019296
- A16D (p.Ala16Asp), Ensembl rs2133470461
- A16T (p.Ala16Thr), rs3218619, ClinGen CA159628, cosmic curated COSV58238, ClinVar RCV000121045, CADD 10.30, PolyPhen-2 0.05, Benign/Likely benign, Autoimmune lymphoproliferative syndrome type 1; not specified; not provided
- A16A (p.Ala16Ala), rs1041779452, gnomAD 10-88989486-A-G, CADD 3.29
- A16* (p.Ala16Ter), rs1848019699, gnomAD 10-89003043-TGC-T, CADD 21.40
- A16P (p.Ala16Pro), gnomAD 10-89003044-G-C, CADD 5.87, PolyPhen-2 0.00
- R17G (p.Arg17Gly), TOPMed rs1848019915, CADD 6.20, PolyPhen-2 0.00
- R17S (p.Arg17Ser), ExAC rs756522969, gnomAD rs756522969, CADD 4.49, PolyPhen-2 0.01
- R17K (p.Arg17Lys), gnomAD 10-88989476-G-A, CADD 0.36
- R17R (p.Arg17Arg), gnomAD 10-89003049-A-G, CADD 2.27
- L18V (p.Leu18Val), ExAC rs764468017, gnomAD rs764468017, CADD 1.43, PolyPhen-2 0.17
- L18I (p.Leu18Ile), rs568447642, gnomAD 10-88989529-C-A, CADD 0.84
- L18P (p.Leu18Pro), rs1267646392, gnomAD 10-88989533-T-C, CADD 0.41
- L18L (p.Leu18Leu), rs2133376687, gnomAD 10-88989534-G-C, CADD 5.44
- S19L (p.Ser19Leu), rs754339875, ClinGen CA5593024, cosmic curated COSV10518, ClinVar RCV003633875, CADD 0.08, PolyPhen-2 0.00, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- S19P (p.Ser19Pro), rs1199807438, ClinGen CA377507326, ClinVar RCV002994457, TOPMed rs1199807438, CADD 0.01, PolyPhen-2 0.00, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- S19S (p.Ser19Ser), rs757754872, gnomAD 10-89003055-G-A, CADD 2.92
- S20G (p.Ser20Gly), rs1246133566, gnomAD 10-88989526-A-G, CADD 4.66
- S20I (p.Ser20Ile), gnomAD 10-88989527-G-T, CADD 0.14
- S20R (p.Ser20Arg), gnomAD 10-88989528-T-A, CADD 6.28
- S20T (p.Ser20Thr), gnomAD 10-89003056-T-A, CADD 0.09, PolyPhen-2 0.04
- K21E (p.Lys21Glu), gnomAD rs1174183388, CADD 7.92, PolyPhen-2 0.29
- K21I (p.Lys21Ile), rs1336686873, gnomAD 10-88989536-A-T, CADD 6.83
- K21K (p.Lys21Lys), gnomAD 10-88989537-A-G, CADD 3.12
- S22S (p.Ser22Ser), rs1381204725, gnomAD 10-89003064-T-C, CADD 0.72
- V23I (p.Val23Ile), rs779039838, ClinGen CA211325363, ClinVar RCV003518431, ClinVar RCV004369165, CADD 4.79, PolyPhen-2 0.03, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1; Inborn genetic diseases
- V23L (p.Val23Leu), ExAC rs779039838, TOPMed rs779039838, gnomAD rs779039838, CADD 4.82, PolyPhen-2 0.12, Uncertain significance
- V23F (p.Val23Phe), gnomAD 10-89003065-G-T, CADD 13.90, PolyPhen-2 0.71
- N24D (p.Asn24Asp), gnomAD rs1457691565, CADD 7.36, PolyPhen-2 0.01
- N24S (p.Asn24Ser), gnomAD 10-88989524-A-G, CADD 4.57
- N24N (p.Asn24Asn), gnomAD 10-88989525-C-T, CADD 5.97
- N24H (p.Asn24His), gnomAD 10-89003068-A-C, CADD 5.90, PolyPhen-2 0.02
- N24K (p.Asn24Lys), gnomAD 10-89003070-T-A, CADD 2.38, PolyPhen-2 0.01
- A25D (p.Ala25Asp), Ensembl rs2133470780
- A25T (p.Ala25Thr), rs606231364, ClinGen CA212971, ClinVar RCV000017972, UniProt VAR 013416, AlphaMissense 0.10, MetaLR 0.79, Pathogenic, FAS-related autoimmune lymphoproliferative syndrome
- A25V (p.Ala25Val), Ensembl rs2133470780
- Q26R (p.Gln26Arg), rs2133470846, ClinGen CA377507409, ClinVar RCV001913620, Ensembl rs2133470846, CADD 1.18, PolyPhen-2 0.12, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- Q26E (p.Gln26Glu), gnomAD 10-88989487-C-G, CADD 0.70
- Q26* (p.Gln26Ter), gnomAD 10-88989487-C-T, CADD 0.86
- Q26H (p.Gln26His), gnomAD 10-88989488-A-ACG, CADD 2.41
- Q26Q (p.Gln26Gln), gnomAD 10-88989489-A-G, CADD 0.47
- Q26P (p.Gln26Pro), rs1293946119, gnomAD 10-88989503-A-C, CADD 2.41
- V27M (p.Val27Met), rs201624874, ClinGen CA211325380, ClinVar RCV002027737, 1000Genomes rs201624874, CADD 8.50, PolyPhen-2 0.29, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- T28A (p.Thr28Ala), UniProt VAR 013417, CADD 4.95, Pathogenic, in ALPS1A
- T28N (p.Thr28Asn), rs1484157800, gnomAD 10-88989544-ACAGA, CADD 4.51
- T28K (p.Thr28Lys), gnomAD 10-88989545-C-A, CADD 5.64
- T28T (p.Thr28Thr), gnomAD 10-88989552-A-G, CADD 6.13
- T28R (p.Thr28Arg), rs1370004258, gnomAD 10-88989563-C-G, CADD 1.43
- T28I (p.Thr28Ile), gnomAD 10-88989563-C-T, CADD 1.74
- D29G (p.Asp29Gly), ExAC rs758551688, TOPMed rs758551688, gnomAD rs758551688, CADD 1.40
- D29D (p.Asp29Asp), rs1323745013, gnomAD 10-89003085-C-T, CADD 0.04
- I30V (p.Ile30Val), gnomAD rs1346855544, CADD 0.00, PolyPhen-2 0.00
- N31S (p.Asn31Ser), ExAC rs780272444, TOPMed rs780272444, gnomAD rs780272444, CADD 0.00, PolyPhen-2 0.00
- N31T (p.Asn31Thr), gnomAD 10-89003090-A-C, CADD 0.00, PolyPhen-2 0.02
- N31N (p.Asn31Asn), rs746762050, gnomAD 10-89003091-C-T, CADD 1.44
- S32F (p.Ser32Phe), TOPMed rs866603022, gnomAD rs866603022, Uncertain significance
- S32Y (p.Ser32Tyr), rs866603022, ClinGen CA377507448, ClinVar RCV001348987, TOPMed rs866603022, CADD 2.79, PolyPhen-2 0.06, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- S32I (p.Ser32Ile), gnomAD 10-88989554-G-T, CADD 5.35
- S32S (p.Ser32Ser), gnomAD 10-88989555-C-T, CADD 0.93
- S32R (p.Ser32Arg), rs1847043174, gnomAD 10-88989555-C-A, CADD 0.70
- S32* (p.Ser32Ter), rs746195443, gnomAD 10-88989560-C-G, CADD 1.70
- S32C (p.Ser32Cys), gnomAD 10-89003093-C-G, CADD 12.50, PolyPhen-2 0.84
- K33E (p.Lys33Glu), rs55766344, ClinGen CA211325393, ClinVar RCV001344165, TOPMed rs55766344, AlphaMissense 0.11, MetaLR 0.77, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- K33Q (p.Lys33Gln), rs55766344, ClinGen CA377507451, ClinVar RCV002004518, TOPMed rs55766344, AlphaMissense 0.11, MetaLR 0.77, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- K33T (p.Lys33Thr), rs2495020118, ClinGen CA377507452, ClinVar RCV003222675, Uncertain significance, not provided
- K33K (p.Lys33Lys), rs1350308710, gnomAD 10-89003097-G-A, CADD 0.56
- G34V (p.Gly34Val), gnomAD 10-88989534-GA-G, CADD 1.85
- G34S (p.Gly34Ser), rs747724138, gnomAD 10-88989538-G-A, CADD 4.54
- G34C (p.Gly34Cys), gnomAD 10-88989538-G-T, CADD 3.97
- G34D (p.Gly34Asp), rs755695651, gnomAD 10-88989539-G-A, CADD 1.32
- G34G (p.Gly34Gly), gnomAD 10-88989540-T-C, CADD 4.93
- G34* (p.Gly34Ter), gnomAD 10-88989541-G-T, CADD 3.67
- G34R (p.Gly34Arg), gnomAD 10-88989541-G-A, CADD 4.24
- G34E (p.Gly34Glu), rs777417894, gnomAD 10-88989542-G-A, CADD 2.26
- L35M (p.Leu35Met), rs9333296, ClinGen CA5593032, ClinVar RCV003090800, 1000Genomes rs9333296, CADD 2.34, PolyPhen-2 0.72, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- L35W (p.Leu35Trp), rs2133471258, ClinGen CA377507466, ClinVar RCV002017764, Ensembl rs2133471258, AlphaMissense 0.09, MetaLR 0.83, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- L35I (p.Leu35Ile), gnomAD 10-88989556-C-A, CADD 0.20
- L35P (p.Leu35Pro), rs1847043329, gnomAD 10-88989557-T-C, CADD 1.23
- L35L (p.Leu35Leu), rs9333296, gnomAD 10-89003101-T-C, CADD 0.09
- E36* (p.Glu36Ter), gnomAD 10-88989547-G-T, CADD 6.18
- E36D (p.Glu36Asp), gnomAD 10-89003106-A-C, CADD 8.40, PolyPhen-2 0.22
- E36E (p.Glu36Glu), gnomAD 10-89003106-A-G, CADD 2.81
- L37* (p.Leu37Ter), rs1564686301, ClinGen CA377507479, ClinVar RCV000704333, Ensembl rs1564686301, Pathogenic
- L37L (p.Leu37Leu), gnomAD 10-89003109-G-A, CADD 1.66
- L37F (p.Leu37Phe), gnomAD 10-89003109-G-T, CADD 15.00, PolyPhen-2 0.97
- R38K (p.Arg38Lys), gnomAD rs1210671749
- R38S (p.Arg38Ser), Ensembl rs1848026668
- R38T (p.Arg38Thr), gnomAD rs1210671749, CADD 5.38, PolyPhen-2 0.23
- R38I (p.Arg38Ile), rs1424538055, gnomAD 10-88989572-G-T, CADD 5.91
- K39* (p.Lys39Ter), rs2495021186, ClinGen CA377507498, ClinVar RCV003517918, Pathogenic
- T40S (p.Thr40Ser), gnomAD 10-89003116-A-T, CADD 5.25, PolyPhen-2 0.00
- V41F (p.Val41Phe), gnomAD rs1848026846, CADD 12.60, PolyPhen-2 0.85
- V41I (p.Val41Ile), gnomAD rs1848026846
- V41E (p.Val41Glu), rs1474732979, gnomAD 10-88989578-T-A, CADD 2.80
- V41V (p.Val41Val), rs1848027052, gnomAD 10-89003121-T-C, CADD 0.55
- T43A (p.Thr43Ala), Ensembl rs2133471460, CADD 0.04, PolyPhen-2 0.00
- T43I (p.Thr43Ile), cosmic curated COSV58238, Ensembl rs2133471492, CADD 4.38, PolyPhen-2 0.01
- V44A (p.Val44Ala), ExAC rs769684168, CADD 0.08, PolyPhen-2 0.00
- V44I (p.Val44Ile), Ensembl rs2133471516, CADD 0.00, PolyPhen-2 0.00
- V44V (p.Val44Val), gnomAD 10-89003130-T-G, CADD 0.29
- E45A (p.Glu45Ala), Ensembl rs2133471555
- T46P (p.Thr46Pro), rs1286527065, ClinGen CA377507577, ClinVar RCV003635021, gnomAD rs1286527065, CADD 0.00, PolyPhen-2 0.01, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- Q47R (p.Gln47Arg), rs553156945, ClinGen CA5593035, ClinVar RCV002994119, ClinVar RCV003170815, CADD 0.04, PolyPhen-2 0.00, Conflicting interpretations, Autoimmune lymphoproliferative syndrome type 1; Inborn genetic diseases
- Q47P (p.Gln47Pro), gnomAD 10-89003138-A-C, CADD 0.15, PolyPhen-2 0.09
- Q47Q (p.Gln47Gln), rs3218621, gnomAD 10-89003139-G-A, CADD 0.57
- N48K (p.Asn48Lys), gnomAD 10-89003142-C-G, CADD 7.79, PolyPhen-2 0.21
- L49M (p.Leu49Met), gnomAD 10-89003143-T-A, CADD 0.28, PolyPhen-2 0.48
- L49S (p.Leu49Ser), gnomAD 10-89003144-T-C, CADD 0.00, PolyPhen-2 0.00
- E50Q (p.Glu50Gln), gnomAD 10-89003146-G-C, CADD 16.80, PolyPhen-2 0.91
- G51D (p.Gly51Asp), Ensembl rs2133471726
- G51S (p.Gly51Ser), Ensembl rs2133471680, CADD 21.60, PolyPhen-2 0.83
- G51C (p.Gly51Cys), gnomAD 10-89003149-G-T, CADD 22.40, PolyPhen-2 0.99
- G51G (p.Gly51Gly), gnomAD 10-89003151-C-T, CADD 1.89
- L52Q (p.Leu52Gln), Ensembl rs2133471749
- L52L (p.Leu52Leu), rs766079591, gnomAD 10-89003154-G-A, CADD 0.74
- H53R (p.His53Arg), ExAC rs774178288, TOPMed rs774178288, gnomAD rs774178288, CADD 12.80, PolyPhen-2 0.39, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- H53Y (p.His53Tyr), gnomAD 10-88989496-C-T, CADD 4.53
- H53D (p.His53Asp), rs764052466, gnomAD 10-88989496-C-G, CADD 4.04
- H53L (p.His53Leu), gnomAD 10-88989497-A-T, CADD 3.10
- H53Q (p.His53Gln), rs754023764, gnomAD 10-88989498-C-A, CADD 0.18
- H53H (p.His53His), rs754023764, gnomAD 10-88989498-C-T, CADD 0.24
- H54R (p.His54Arg), rs759152311, ClinGen CA5593040, ClinVar RCV001063405, ExAC rs759152311, CADD 0.00, PolyPhen-2 0.00, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- H54H (p.His54His), gnomAD 10-89003160-T-C, CADD 0.74
- D55G (p.Asp55Gly), TOPMed rs1363092780, gnomAD rs1363092780, CADD 0.00, PolyPhen-2 0.00
- D55H (p.Asp55His), rs148677058, ClinGen CA5593041, ClinVar RCV001939059, ClinVar RCV003303433, CADD 6.08, PolyPhen-2 0.00, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1; Inborn genetic diseases
- D55Y (p.Asp55Tyr), gnomAD 10-89003161-G-T, CADD 8.06, PolyPhen-2 0.04
- G56D (p.Gly56Asp), cosmic curated COSV10589, TOPMed rs1452698941, gnomAD rs1452698941, CADD 0.03, PolyPhen-2 0.06
- G56S (p.Gly56Ser), gnomAD 10-89003164-G-A, CADD 1.68, PolyPhen-2 0.16
- Q57Q (p.Gln57Gln), rs1163621042, gnomAD 10-89003169-A-G, CADD 0.13
- F58L (p.Phe58Leu), Ensembl rs2133471982
- C59F (p.Cys59Phe), rs886047459, ClinGen CA10636825, ClinVar RCV000277378, TOPMed rs886047459, CADD 23.90, PolyPhen-2 1.00, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- C59S (p.Cys59Ser), rs2495023352, ClinGen CA377507726, ClinVar RCV003517617, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- C59Y (p.Cys59Tyr), TOPMed rs886047459, gnomAD rs886047459, CADD 23.80, PolyPhen-2 1.00, Uncertain significance
- H60R (p.His60Arg), rs753767914, ClinGen CA211325448, cosmic curated COSV58240, ClinVar RCV001974894, CADD 14.90, PolyPhen-2 0.00, Uncertain significance, Autoimmune lymphoproliferative syndrome type 1
- H60Y (p.His60Tyr), gnomAD 10-89003176-C-T, CADD 15.90, PolyPhen-2 0.06
- H60H (p.His60His), gnomAD 10-89003178-T-C, CADD 1.24
- K61* (p.Lys61Ter), gnomAD 10-89003177-A-AT, CADD 24.00
- K61E (p.Lys61Glu), gnomAD 10-89003179-A-G, CADD 10.30, PolyPhen-2 0.01
- K61K (p.Lys61Lys), rs3218613, gnomAD 10-89003181-G-A, CADD 0.89
- P62H (p.Pro62His), ExAC rs757780022, TOPMed rs757780022, gnomAD rs757780022, CADD 16.90, PolyPhen-2 0.93, Uncertain significance
Public FAS analysis runs
- FAS analysis run — FAS (643 variants) — completed 2026-08-21